BioCentury
ARTICLE | Clinical News

Onyvax-105: Phase I/II data

April 25, 2005 7:00 AM UTC

Data from a U.K. Phase I/II trial in 31 patients showed that 2 patients remain disease free 5.8 and 6.5 years after their original diagnosis. About 71% of patients showed measurable T cell responses w...